Generic drug

| Ethics in Corporate Society | | PHARMACEUTICAL MARKETING-the growing ethical concern? Analytical Report | | | Madiha Raza Noama Naeem Sheikh Zargham Zaigham LETTER OF AUTHORIZATION November 5, 2011 Dear Readers, As students of BBA, our course instructor of Ethics in Corporate Society, Ms. Tania Danish authorized us to make a report on the “PHARMACEUTICAL MARKETING-the growing ethical concern?” We were required to make a report in accordance to our learning in the course

presented on October 15, 2014. First I will provide a summary of the prosecution history behind this case. Teva Pharmaceuticals USA created a multiple sclerosis drug called Copaxone and subsequently obtained a patent for the drug. Sandoz Inc. desired to create a generic version of Copaxone and submitted their request to the Food and Drug Administration. In 2012, Teva sued Sandoz in the U.S. District Court for the Southern District of New York on the grounds of patent infringement. The District Court

High-Technology Acquisitions Final Project -Acquisition Proposal: To Acquire: May 2012 Table of Content Executive Summary I A. Purpose I B. Background I C. The Rational for the Acquisition I D. Standalone, Synergy and Premium Valuations II E. Integration Plan II Part 1 - The Rational of the Acquisition 1 1. Pfizer's Strategy 1 1.1. Pfizer Growth Strategy 2 2. Pfizer's Road Map 4 2.1. Pfizer's Acquisitions Rational 4 3. The strategy behind the acquisition

Strategic Analysis for Pfizer Incorporated Strategic Analysis Competition, typically the most powerful external force, is increased by the advent of globalization. The number of companies and the number of countries where these companies operate and the way governments are dealing with the impacts of globalization is accelerating. The interaction of changes in government policy and business innovation has actually made globalization even faster. If a company does not become a global, it would

• Teva Pharmaceuticals- Founded in 1901, Teva is a large Israeli pharmaceutical company based in Petah Tikva. This company focuses on generic and proprietary products. They are the largest generic pharmaceutical manufacturer in the world and the 15th largest pharmaceutical company. This company has operations in 5 continents and is listed in the NYSE and in the Tel Aviv Stock Exchange. Teva Pharmaceuticals has 4

business. Meanwhile, this company doesn’t able to achieve its goal because of some issues. This aims to solve its problem but unintentionally the issue was covered by another issue during the time of resolution. Namely Cheap Pharma Inc. (CPI) a generic drug company is suffering from low sales and small profits and possibly little earnings from its business. As a solution for its problem, Mr. De Guzman and the two other board of directors of the Cheap Pharma initiated to buy shares to GreenMed (GM)

TEGNA Inc. hosted an investor day to unveil the Company’s growth strategy after the spin-off from Cars.com is complete. The consensus from the analyst reports were cautiously optimistic. Stephens Inc. and The Benchmark Company, LLC reported positively on TEGNA’s new growth model, but will continue to hold reservations until the spin-off is complete.   David Lougee stepped into an early leadership role in the meeting by providing concrete revenue focal points for the Company during the presentation

EXECUTIVE SUMMARY The purpose of this report is to critically analyse and discuss the key strategies and recommendations for Hovid Berhad's intention to setup an international business by expanding its business overseas. This report shows the understanding on the current international business issues and selected strategies for the international business environment hence, China is recommended for the expansion by forming a strategic alliance with China Nepstar Chain Drugstore Ltd. This report

Case Background: Founded in 1876, Eli Lilly is a pharmaceutical company that completes nearly every step of the product supply chain internally. The company researches, develops, produces and sells a large variety of agricultural products as well as human healthcare items. Over the past century, Eli Lilly has risen to become one of the largest and most successful pharma companies in the USA. In 1992, the year of Eli Lilly-Ranbaxy Private Limited joint venture (ELR), the company’s products were

Under his leading, Merck opened up several therapeutic areas and enhanced its reputation for bringing “blockbusters” to drug market. During the 1980s, Merck’s sales more than doubled and profits tripled. During 1987-1990, Merck ranked in top 10 most valuable companies in Businessweek. 2. Problem Statement Merck & Co. is a global leading position pharmaceutical company that is into drug research and production. However Merck suffered market share